Matching articles for "nadofaragene firadenovec"
In Brief: Adstiladrin – A Gene Therapy for Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • March 6, 2023; (Issue 1671)
Nadofaragene firadenovec-vncg (Adstiladrin – Ferring), an adenoviral vector-based gene therapy,
has been approved by the FDA for treatment of adults
with high-risk Bacillus Calmette-Guérin...
Nadofaragene firadenovec-vncg (Adstiladrin – Ferring), an adenoviral vector-based gene therapy,
has been approved by the FDA for treatment of adults
with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer
(NMIBC) with carcinoma in situ with or without
papillary tumors. It is the first adenoviral vector-based
gene therapy to be approved in the US for
this indication. The immune checkpoint inhibitor
pembrolizumab (Keytruda) was approved for the
same indication in 2021.